

BMJ Open Respiratory Research

Smoking and socioeconomic factors linked to acute exacerbations of COPD: analysis from an Asthma + Lung **UK** survey

Parris J Williams ¹ Andrew Cumella, ² Keir Elmslie James Philip ¹ Anthony A Laverty ¹ , ³ Nicholas S Hopkinson ¹

To cite: Williams PJ. Cumella A, Philip KEJ, et al. Smoking and socioeconomic factors linked to acute exacerbations of COPD: analysis from an Asthma + Lung UK survey. BMJ Open Resp Res 2022;9:e001290. doi:10.1136/ bmjresp-2022-001290

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/bmjresp-2022-001290).

Received 29 April 2022 Accepted 27 June 2022

1.59).

ABSTRACT

and well-being.

the charity Asthma + Lung UK.

Background Understanding the factors driving acute

exacerbations of chronic obstructive pulmonary disease

(COPD) is key to reducing their impact on human health

Methods 5997 people with COPD, mean 66 years, 64%

female, completed an online survey between December

2020 and May 2021 about living with COPD, developed by

Results The 3731 (62.2%) survey participants reporting

frequent (≥2/year) exacerbations were more likely to

smoke (adjusted OR (AOR) 1.70, 95% CI 1.470 to 1.98),

have lower annual household income (≤£20 000 (AOR

(AOR 1.78, 95% CI 1.50 to 2.11) and report previous

occupational exposure to dust, fumes and chemicals.

Smokers were more likely to report attending hospital to

manage their most recent acute exacerbation of COPD

compared with ex-smokers (AOR 1.25, 95% CI 0.99 to

Discussion Strategies to improve COPD outcomes must address issues of deprivation and social justice.

1.72, 95% CI 1.36 to 2.17), live in a cold and damp home

BMJ.

³Department Primary Care and Public Health, Imperial College London School of Public

Correspondence to Professor Nicholas S Hopkinson: n.hopkinson@ic.ac.uk

BMJ

INTRODUCTION Chronic obstructive pulmonary disease is highly prevalent, with at least 1.3 million people diagnosed in the UK, and rates increasing over the past decade. COPD is known to be less common in affluent populations. The gap in COPD mortality has widened dramatically in recent years, being five times higher in the lowest income decile than the highest in 2020 compared with twice as high in 2010. 12 Acute exacerbations of COPD (AECOPD) in patients lead to a higher risk of hospitalisation and mortality; increased exposure to infectious pathogens, environmental pollutants and poor physical fitness are established risk factors. More than 50% of the cost of COPD is attributable to exacerbation management,³ so prevention is an important issue for sustainability of healthcare systems as well as for individual patients.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Acute exacerbations of COPD are costly both in terms of patient quality of life and health service cost. Infections, poor cardiorespiratory fitness and environmental pollutants are known drivers of COPD exacerbations.

WHAT THIS STUDY ADDS

⇒ This study adds to growing evidence that socioeconomic factors including poor housing conditions and low incomes may increase the frequency of acute exacerbations among people with COPD in the UK.

HOW THIS STUDY MIGHT AFFECT RESEARCH, **PRACTICE OR POLICY**

⇒ This study highlights the need for more research and funding, addressing the harmful effects of social deprivation on COPD health within the UK.

Information about the impact of disparities in wealth and other specific housing, social and environmental factors is needed to drive efforts to address this.

We therefore made use of data from an online survey, conducted to investigate COPD patient experience, to examine which factors were associated with an increased risk of AECOPD.

METHODS

The paper describes a secondary analysis using data from an online Asthma + Lung UK annual COPD survey conducted from December 2020 to May 2021. This was advertised via social media, direct email messages to the charity's known supporter base and via its website. The full survey is available online (online supplemental file 1). Participants completing the questionnaire consented to their anonymised data being used for research purposes.



@ Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by

¹National Heart and Lung Institute, Imperial College London, London, UK ²Asthma+Lung UK, London,

Health, London, UK





Statistical analysis

Descriptive results are presented as number (%) and mean (SD) as appropriate. Logistic regression results are presented as adjusted ORs (AOR) with 95% CI. Responses to the survey question, 'In the past 12 months, how many exacerbations or "flare-ups" of your COPD symptoms have you had?' were grouped into 0–1 (infrequent) and ≥2 (frequent exacerbators), in line with current treatment guidelines. We also compared participants who did or did not report requiring hospitalisation for an AECOPD in the preceding year. All regression analyses included age, gender and smoking status as independent covariates. Ex-smokers, no previous occupational exposure to airborne pollutants, warm and dry housing and household income ≥£40 000 were used as reference categories for the multiple regression analyses.

RESULTS

The initial sample included 8232 responses. After cleaning for outliers, removing duplicate and incomplete

responses, 5997 responses remained and were analysed. The sample population was majority female (64.4%), white ethnicity (99%) and ex-smokers (80.7%). Mean age was 66.2 (8.9) years (table 1).

The 3731 frequent exacerbators were more likely to be current smokers (AOR: 1.70, 95% CI 1.47 to 1.98), have low annual household (HH) incomes (≤£20000 (AOR: 1.72, 95% CI 1.36 to 2.17), live in cold and damp housing (AOR: 1.78, 95% CI 1.50 to 2.11), report previous occupational exposure to airborne pollutants (AOR: 1.12, 95% CI 1.00 to 1.25) and be male (AOR: 1.32, 95% CI 1.17 to 1.49) (table 2, figure 1).

Among the 532 (8.9%) of survey respondents who reported a hospital attendance to manage their most recent AECOPD, 117 (22%) were current smokers. Smokers were more likely to report hospitalisation compared with ex-smokers (AOR: 1.25, 95% CI 0.99 to 1.59). Both low income and cold and damp housing covariates were numerically higher in those reporting

Table 1 Sociodemographic characteristics of the survey respondents sample including percentage of the sample demographics in each exacerbation group

	AU 11 1 5007	≥2 exacerbations in past 12	0–1 exacerbations in the past 12 months
Demographics	All participants n=5997	months n=3731	n=2266
Age (mean SD)	66.2 ± (8.9)		_
Age started smoking (mean SD)	15.7 ± (4.9)	-	-
Female	3858 (64.3%)	2338 (62.6%)	1520 (67.0%)
Male	2139 (35.7%)	1393 (37.4%)	746 (33.0%)
Ethnicity			
White	5910 (98.5%)	3696 (99.0%)	2179 (97.0%)
Mixed	43 (0.7%)	21 (0.6%)	22 (1.0%)
Asian, Asian British	36 (0.4%)	12 (0.3%)	24 (1.1%)
Black, black British	8 (0.13%)	2 (0.1%)	6 (0.9%)
Household income			
≤£20 000	3061 (51.0%)	2037 (54.5%)	1025 (45.2%)
£20 000–£30 000	1229 (20.5%)	722 (19.3%)	507 (22.3%)
£30 001–£40 000	450 (7.5%)	250 (6.7%)	200 (8.8%)
≥£40 001	343 (5.7%)	183 (5.1%)	160 (7.2%)
Rather not say	913 (15.2%)	539 (14.4%)	374 (16.5%)
Smoking status			
Ex-smoker	4845 (80.8%)	2874 (77.1%)	1971 (86.9%)
Current	1152 (19.2%)	857 (22.9%)	295 (13.1%)
Housing conditions			
Warm and dry	4494 (74.9%)	2642 (70.8%)	1852 (82.2%)
Cold and damp	809 (13.4%)	591 (15.8%)	215 (10.0%)
Cold	470 (7.8%)	339 (9.0%)	77 (4.4%)
Damp	227 (3.9%)	159 (4.4%)	68 (3.4%)
Occupational exposure to dust, fu	mes and chemicals		
Yes	3010 (50.1%)	1965 (52.6%)	1045 (46.1%)
No	2987 (49.9%)	1766 (47.4%)	1221 (53.9%)



Table 2 Factors associated with increased number of exacerbations among survey population

	Model 1: age, sex tobacco and income OR and CI	Model 2: age, sex, tobacco and housing OR and CI	Model 3: all variables OR and CI
Variable			
Gender female	Ref	Ref	Ref
Male	1.38 (1.23 to 1.54)	1.32 (1.18 to 1.48)	1.32 (1.17 to 1.49)
Age	0.97 (0.96 to 0.97)	0.97 (0.96 to 0.98)	0.97 (0.96 to 0.98)
Smoking status (current)	1.68 (1.45 to 1.95)	1.77 (1.53 to 2.06)	1.70 (1.47 to 1.98)
Ex-smokers	Ref	Ref	Ref
Occupational exposure to dust, fume and chemicals	-	-	1.12 (1.00 to 1.25)
No occupational exposure to dust, fumes and chemicals	-	-	Ref
Age started smoking	_	_	1.001 (0.990 to 1.012)
Housing: warm and dry	_	Ref	Ref
Housing: cold and damp	-	1.83 (1.54 to 2.17)	1.78 (1.50 to 2.11)
Housing: cold	-	1.69 (1.37 to 2.09)	1.61 (1.30 to 2.00)
Housing damp	-	1.52 (1.13 to 2.05)	1.49 (1.01 to 2.00)
HH income: ≤£20 000	1.82 (1.45 to 2.30)	-	1.72 (1.36 to 2.17)
HH income: £20 001- £30 000	1.32 (1.03 to 1.68)	_	1.27 (0.99 to 1.63)
HH income: £30 001- £40 000	1.11 (0.83 to 1.48)	-	1.08 (0.81 to 1.44)
HH income: ≥£40000	Ref	-	Ref
HH income: rather not say	1.46 (1.13 to 1.88)	-	1.40 (1.08 to 1.82)

hospitalisation, but these differences were not statistically significant (online supplemental file 1).

DISCUSSION

This large online survey of the experience of people living with COPD provides important contemporary data on the role that socioeconomic factors may play




Figure 1 Sociodemographic, housing and annual household (HH) income factors (AOR, 95%Cl) associated with ≥ 2 exacerbations in the past 12 months among the survey population. Occupational exposure = yes to occupational exposure to dust, fumes and chemicals. Ex-smokers, no occupational exposure, warm and dry housing and HH income > £40,000 were used as reference categories for the analysis.

in AECOPD. We found that low income, poor housing quality, past occupational exposure to airborne pollutants and current smoking were all significantly associated with higher AECOPD frequency. Current smoking was also associated with an increased risk of AECOPD requiring hospitalisation.

A key objective in COPD care is to reduce the frequency of AECOPD, both to improve patients' quality of life and to limit as far as possible the avoidable use of finite healthcare resources. However, there is a huge unmet care need among patients with COPD within the UK, with a large proportion of patients missing out on important COPD care such as self-management plans, vaccinations, pulmonary rehabilitation and smoking cessation, ^{5 6} all of which are proven interventions for reducing AECOPD. The COVID-19 pandemic has worsened this unmet need further, as people with respiratory disease have had trouble accessing healthcare. 7-9 Asthma + Lung UK survey data show that over 75% COPD patients report not receiving basic care during 2020/2021.4 Switching to a digital by default model, further risks excluding deprived and older patients.

Despite the known link between housing quality and health (particularly excess winter deaths), and the 2015 National Institute for Healthcare and Excellence guidance that recommends that healthcare providers assess housing quality and make referrals where necessary, ¹⁰ the effect of housing quality on COPD health has been little studied. Current guidance for housing temperature in



the winter is a minimum of 18°C,¹⁰ but this may not be sufficient for people with COPD. A 2008 paper reported that greater time spent with an indoor temperature ≥21°C was associated with better self-reported health status in people with COPD.¹¹ Of note, data from the Office for Health Improvement and Disparities show that in 2018 2.4 million people in England were living in fuel poverty.¹ More than 70% of survey participants fell below the UK median household income of £31 004, and the impact of housing conditions on AECOPD reflects that, though the link with cold / damp housing was independent of income.

It is well established that austerity policies, which have reduced both social and healthcare support, have had significant impact on the most vulnerable in society, in particular people living with long-term health conditions. Our findings underline this, with poorer survey respondents almost twice as likely to be in the frequent exacerbator group. This is especially relevant as fuel poverty is increasing, and the results illustrate several aspects of the structural violence (where 'violence is built into the structure and shows up as unequal life chances' 13), to which people with COPD are subject. 14

The survey also highlights an important link between smoking, AECOPD frequency and hospitalisations, adding further urgency to the need for strategies to deliver the UK government's smokefree2030 ambition. ¹⁵ ¹⁶

The survey design has some limitations. First, it required some digital literacy, which may have excluded a portion of the COPD population in the UK. Second, there is likely to have been some degree of responder and recall bias. Third, we did not independently validate household income or housing conditions, and we were unable to triangulate index of deprivation as we did not have postcode data. However, we believe that the use of household income as a measure of SES is a robust approach. In addition, the survey population was overwhelmingly white, so caution is needed extrapolating to other ethnic groups, and positive efforts to capture their experience are needed in the future. Finally, the studied cohort are likely to be individuals who were motivated to engage with online surveys and the Asthma + Lung UK charity. These factors may limit generalisability of the findings and may have led to an underestimate of the true impact on SES and housing quality on AECOPD.

In conclusion, these data add to the growing evidence that socioeconomic status, in particular poor housing conditions, are linked to increased frequency of AECOPD. Addressing social deprivation, with a multiagency approach at national and local government level and across health and social care is essential to reduce inequalities and treat the causes of the causes of AECOPD in the UK. In doing so, this will improve the sustainability of healthcare and improve the lives of people with COPD across the UK.

Twitter Nicholas S Hopkinson @COPDdoc

Contributors NSH, PW, AC and AL designed the study. PW and AL analysed the data and PJW produced the first draft to which all authors contributed. All authors have reviewed and approved the final version. NSH is the guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests NSH is Chair of Action on Smoking and Health and Medical Director of Asthma + Lung UK. AL is a Trustee of Action on Smoking and Health. Other authors have no conflict of interest to declare.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Ethical approval was granted by the Imperial College Research Governance and Integrity Team (ICREC Ref: 20IC6625). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Anonymised research data will be shared with third parties via request to Asthma + Lung UK.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Parris J Williams http://orcid.org/0000-0001-8027-1879 Keir Elmslie James Philip http://orcid.org/0000-0001-9614-3580 Anthony A Laverty http://orcid.org/0000-0003-1318-8439 Nicholas S Hopkinson http://orcid.org/0000-0003-3235-0454

REFERENCES

- 1 Office for health improvement and disparities. Inhale INteractive Health Atlas of Lung conditions in England, 2022. Available: https://fingertips.phe.org.uk/profile/inhale/data#page/7/gid/800003/pat/159/par/K0200001/ati/15/are/E92000001/iid/1204/age/1/sex/4/cat/-1/ctp/-1/yrr/1/cid/4/tbm/1/page-options/eng-vo-1_ine-pt-0_ine-vo-0_ine-yo-1:2020:-1:-1_ine-ct-1
- 2 Hopkinson NS. COPD, smoking, and social justice. Lancet Respir Med 2022;10:428–30.
- 3 Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. *Ther Adv Chronic Dis* 2014;5:212–27.
- 4 Asthma + Lung UK. Failing on the fundamentals: our COPD report. Asthma + Lung UK, 2021. https://www.blf.org.uk/support-for-you/copd/world-copd-day/failing-on-the-fundamentals-our-copd-report
- 5 Philip K, Gaduzo S, Rogers J, et al. Patient experience of COPD care: outcomes from the British lung Foundation patient Passport. BMJ Open Respir Res 2019;6:e000478.
- 6 Hopkinson NS, Molyneux A, Pink J, et al. Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance. BMJ 2019;366:I4486.
- 7 Philip KEJ, Lonergan B, Cumella A, et al. COVID-19 related concerns of people with long-term respiratory conditions: a qualitative study. BMC Pulm Med 2020;20:319.
- 8 Wu F, Burt J, Chowdhury T, et al. Specialty COPD care during COVID-19: patient and clinician perspectives on remote delivery. BMJ Open Respir Res 2021;8:e000817.
- 9 Philip KEJ, Buttery S, Williams P, et al. Impact of COVID-19 on people with asthma: a mixed methods analysis from a UK wide survey. BMJ Open Respir Res 2022;9:e001056.
- 10 National Institute for Health Care and Excellence. Excess winter deaths and illness and the health risks associated with cold homes. National Institute for Health Care and Excellence, 2015.



- 11 Osman LM, Ayres JG, Garden C, et al. Home warmth and health status of COPD patients. Eur J Public Health 2008;18:399–405.
- 12 Stuckler D, Reeves A, Loopstra R, et al. Austerity and health: the impact in the UK and Europe. Eur J Public Health 2017;27:18–21.
- 13 Galtung J. Violence, peace, and peace research. *J Peace Res* 1969;6:167–91.
- 14 Buttery SC, Zysman M, Vikjord SAA, et al. Contemporary perspectives in COPD: patient burden, the role of gender and trajectories of multimorbidity. Respirology 2021;26:419–41.
- All Party parliamentary group on smoking and health. delivering a Smokefree 2030: the all Party parliamentary group on smoking and health recommendations for the tobacco control plan 2021, 2021. Available: https://ashorguk/about-ash/all-partyparliamentary-group-on-smoking-health/inquiries-reports/ deliveringasf2030appgtcp2021/
- 16 Mahase E. Legal smoking age in England should rise every year, review recommends. BMJ 2022;377:o1432.